Background: Intracoronary brachytherapy has significantly reduced the recurrence of in-stent restenosis. The aim of this study was to evaluate the feasibility, safety and efficacy of intracoronary beta-radiation in patients at very high risk for recurrence of in-stent restenosis.

Methods: We analyzed 42 patients with 50 lesions submitted to catheter-based beta-radiation (Beta-Cath System, Novoste Corporation, Norcross, GA, USA) for in-stent restenosis. Thirty-eight lesions were at the second restenosis, 8 at the third, and 4 at the fourth; a diffuse pattern was present in 78%.

Results: Balloon angioplasty was performed for 30 lesions (60%) and the cutting balloon technique for 20 (40%). In 12 lesions further 14 stents had to be deployed (28%). The delivery catheter was successfully positioned in 96% of the procedures. The mean dwell time was 179 +/- 50 s with a radiation dose ranging from 18.4 to 25.3 Gy, depending on the vessel size. A complete angiographic success without coronary dissection and without any additional stenting after radiation delivery was achieved in 86%. At follow-up (7.2 +/- 2.1 months), the overall restenosis rate was 30.4% (14 lesions). A recurrence was detected in 1/11 lesions with initial focal pattern and in 13/39 lesions with initial diffuse pattern. The restenosis rate was higher in patients in whom a geographic miss had occurred (p < 0.05 vs lesions without geographic miss) and in those in whom a new stent had been deployed (p < 0.05 vs lesions treated without a stent).

Conclusions: Brachytherapy reduces the in-stent restenosis rate in patients who are at very high risk of recurrence. The restenosis pattern, geographic miss and new stent deployment seem to be negative prognostic factors for recurrence of restenosis.

Download full-text PDF

Source

Publication Analysis

Top Keywords

in-stent restenosis
16
patients high
12
high risk
12
risk recurrence
12
recurrence in-stent
12
restenosis rate
12
restenosis
9
lesions
9
intracoronary beta-radiation
8
diffuse pattern
8

Similar Publications

Background: Drug-coated balloons present a potentially advantageous therapeutic approach for managing coronary in-stent restenosis (ISR). However, the comparative benefits of paclitaxel-coated balloons (PCBs) over uncoated balloons (UCBs) remain unclear.

Aims: We conducted a systematic review and meta-analysis to evaluate and compare the clinical outcomes of patients treated with PCBs and UCBs.

View Article and Find Full Text PDF

The optimal intervention for in-stent restenosis: Unravelling Ariadne's thread.

Cardiovasc Revasc Med

December 2024

First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece.

View Article and Find Full Text PDF

Baicalin-based composite coating for achieving biological multifunctionality of vascular stents.

J Control Release

January 2025

Institute of Biomedical Engineering, College of Medicine, Southwest Jiaotong University, Chengdu 610031, PR China. Electronic address:

Vascular stents are frequently used in interventional therapy for atherosclerotic arteries. Interventional treatment with bare metal stents and drug-eluting stents has significantly reduced mortality. Restenosis and late thrombus were also major safety concerns in stent implantation.

View Article and Find Full Text PDF

Peritherapeutic intra-arterial flow changes predict long-term stent patency in patients with severe intracranial artery stenosis receiving PTAS.

Eur J Radiol

December 2024

Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan; School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan. Electronic address:

Background And Purpose: The quantitative intra-arterial flow dynamics following percutaneous transluminal angioplasty and stenting (PTAS) for severe intracranial artery stenosis have never been investigated. We aimed to evaluate peritherapeutic intracranial artery flow dynamics following PTAS with quantitative magnetic resonance angiography (qMRA) to predict long-term stent patency.

Design: This is a prospective, single-center study.

View Article and Find Full Text PDF

Recurrent drug eluting stent, in-stent restenosis (DES-ISR): Epidemiology, pathophysiology & treatment.

Prog Cardiovasc Dis

January 2025

Division of Cardiovascular Medicine, Department of Medicine, University of Virginia Health System, 1215 Lee Street, Charlottesville, VA 22909, United States of America. Electronic address:

Coronary artery in-stent restenosis (ISR) is driven by neointimal hyperplasia and neoatherosclerosis in previously placed stents. Drug eluting stents (DES) have been adopted as first line therapy for the initial episode of ISR. However, recurrent ISR has limited durable salvage options.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!